Work

A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy

Year: 2025

Type: article

Abstract: catalytic prodrug activation and immunomodulation. Particularly, localized activation of a doxorubicin prodrug kills tumor cells and induces immunogenic cell death (ICD), thereby releasing tumor-associated antigens and priming personalized antitumor immunity. Concurrently, dendritic cell membrane-derived ligand-receptor interactions facilitate T cell activation and proliferation. This synergistic strategy enables efficient antigen presentation and robust immune activation. The presented approach offers a versatile paradigm for engineering catalytic aAPCs toward bioorthogonal cancer immunotherapy.

Source: Chemical Science

DOI: 10.1039/d5sc06284e

Authors: Zhengwei Liu, Wenting Zhang, Chuanqi Zhao, Mengyu Sun, Jinsong Ren, Xiaogang Qu